Safety, efficacy, and cardiovascular benefits of combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists in patients with diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

Article (Faculty180)

cited authors

  • Mousavi, Asma; Shojaei, Shayan; Soleimani, Hamidreza; Semirani-Nezhad, Davood; Ebrahimi, Pouya; Zafari, Ali; Ebrahimi, Rasoul; Roozbehi, Khatere; Harrison, Anil; Syed, Mushabbar A; Kuno, Toshiki; Askari, Mani Khorsan K; Almandoz, Jaime P; Jun, John; Hosseini, Kaveh

description

  • <p>The potential benefits and risks of combination therapy with sodium-glucose co-transporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) versus monotherapy remain a subject of debate to optimize metabolic and cardiovascular outcomes in patients with type 2 diabetes mellitus. This study aims to systematically review and meta-analyze the available evidence from randomized controlled trials.</p>

authors

publication date

  • 2025

published in

start page

  • 68

volume

  • 17